Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional ...
Research and Development (R&D) Expenses: R&D expense was $32.7 million for the first quarter of 2026, as compared to $19.6 ...
Blavity on MSN
Kehlani on navigating life with bipolar disorder and BPD
In the world of contemporary R&B, Kehlani has long been celebrated for a radical brand of transparency that mirrors the ...
World Bipolar Day 2026 highlights awareness, understanding, and the need to challenge common myths surrounding bipolar disorder while promoting accurate information and empathy. A person may appear ...
ABSTRACT: Lithium remains the most effective long-term treatment for bipolar disorder, yet its therapeutic benefits are offset by a well-established risk of chronic kidney disease (CKD). Anticipating ...
ABSTRACT: Anticipating short-term affective instability in bipolar disorder represents a longstanding challenge in computational psychiatry. Early signalling of transitions from stable to depressive, ...
ATLANTA, March 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer ...
(RTTNews) - LB Pharmaceuticals Inc. (LBRX), a clinical-stage biopharmaceutical company, announced the initiation of a Phase 2 trial of investigational drug LB-102 in bipolar depression, dubbed ...
(The Conversation) – Have you ever tossed and turned under a full moon and wondered if its glow was keeping you awake? For generations, people have believed that the Moon has the power to stir up ...
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results